Arg-Gly-Asp-Ser
CAS No. : 91037-65-9

Arg-Gly-Asp-Ser
Cat. No. : CS-3266
M. Wt. : 433.42
Size Stock Price Quantity Add to Cart Quotation Online
5mg In-stock $60.0
10mg In-stock $89.0
50mg In-stock $234.0
Products are for research use only. Not for human use. We do not sell to patients.

Bulk Inquiry

Collapse
Your information is safe with us. * Required Fields
  Salutation:
  • Dr.
  • Prof.
  • Mr.
  • Ms.
  • Mrs.
  • Miss.
*Country or Region:
  • United States
  • Canada
  • United Kingdom
  • Australia
  • China
  • Germany
  • France
  • Japan
  • Korea South
  • Switzerland
  • ----------------------------------
  • Albania
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Azerbaijan
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Bolivia
  • Bosnia Herzegovina
  • Brazil
  • Bulgaria
  • Cameroon
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Cyprus
  • Czech Republic
  • Denmark
  • Ecuador
  • Egypt
  • Estonia
  • Fiji
  • Finland
  • France
  • Georgia
  • Germany
  • Gibraltar
  • Greece
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Korea South
  • Kuwait
  • Latvia
  • Lebanon
  • Libya
  • Lithuania
  • Luxembourg
  • Macedonia
  • Malaysia
  • Malta
  • Mexico
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Morocco
  • Nepal
  • Netherlands
  • New Zealand
  • Nigeria
  • Norway
  • Oman
  • Pakistan
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Republic of Benin
  • Romania
  • Russia
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sri Lanka
  • Suriname
  • Sweden
  • Switzerland
  • Syria
  • Thailand
  • Tunisia
  • Turkey
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • Uruguay
  • Uzbekistan
  • Venezuela
  • Vietnam
  • Zambia
  • Zimbabwe
  • Other Countries
* Applicant name:
* Organization Name:
* Email address:
* Requested quantity:
  • ug
  • g
  • kg
  • t
  • mL
  • L
* Phone number:
  Remarks:
 
Name, 
Organization Name, 
Email address, 
Requested quantity, 
Phone number, 
  • Data Sheet

  • Introduction

  • SDS

  • COA & Spectra

Name: Arg-Gly-Asp-Ser; RGDS peptide; Fibronectin Inhibitor
Cat. No. : CS-3266
CAS No. : 91037-65-9
Formula: C15H27N7O8
M. Wt. : 433.42
Solubility: DMSO: ≥ 55 mg/mL

Activity:

Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9. In Vitro: The Arg-Gly-Asp-Ser-modified surface causes up-regulation of αvβ3 integrin. Attachment to the Arg-Gly-Asp-Ser-treated membrane completely abolishes apoptosis induced by staurosporine, the Ca2+·Pi ion pair, and sodium nitroprusside. Arg-Gly-Asp-Ser-dependent resistance to apoptosis is eliminated, when the activity of the phosphatidylinositol 3-kinase pathway is inhibited[1]. Arg-Gly-Asp-Ser interacts with survivin, as well as with procaspase-3, -8 and -9. Arg-Gly-Asp-Ser-peptide binding to survivin is found to be specific, at high affinity (Kd 27.5 μM) and locates at the survivin C-terminus. Arg-Gly-Asp-Ser-survivin interaction appears to play a key role, since Arg-Gly-Asp-Ser lost its anti-mitogenic effect in survivin-deprived cells with a specific siRNA[4]. In Vivo: Arg-Gly-Asp-Ser (2.5 or 5 mg/kg, 1 h before LPS) significantly inhibits LPS-induced MMP-9 activity in BAL fluid 4 h post-LPS. Arg-Gly-Asp-Ser (1, 2.5 or 5 mg/kg, i.p.) administers 1 h before LPS inhibited LPS-induced increases in TNF-α and MIP-2 levels in BAL fluid at 4 h post-LPS[2]. Arg-Gly-Asp-Ser peptide significantly reduces tumor necrosis factor (TNF)-α and macrophage inflammatory protein (MIP)-2 production, and decreases myeloperoxidase (MPO) and NF-κB activity[3].

Protocol:

Cell Assay: [1]Cell death is measured using the MTT analysis. This assay is based on the ability of mitochondrial dehydrogenases to oxidize thiazolyl blue (MTT), a tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylterazolium bromide), to an insoluble blue formazan product. The cells are incubated with the MTT reagent (120 μg/mL) at 37°C for 2 h. After the supernatant is removed, 400 μL of 0.04mol/LHCl in isopropanol is added to each well, and the optical density of the solution is read at 590 nm in an enzyme-linked immunosorbent assay plate reader. As the generation of the blue product is proportional to the dehydrogenase activity, a decrease in the absorbance at 590 nm provides a direct measurement of the number of viable cells. To determine the contribution of the PI3K pathway to inhibition of apoptosis, some cell populations are pretreated with 50 μM LY294002, a PI3K inhibitor. Following this pretreatment, cell death is determined as described above. Animal Administration: Arg-Gly-Asp-Ser is formulated in sterile saline (0.9% NaCl).[2]Mouse pharyngeal aspiration is performed as described. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with Arg-Gly-Asp-Ser or RGES peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered Arg-Gly-Asp-Ser or RGES peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS 

References:

Yin X, et al. Synthetic RGDS peptide attenuated lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice. J Gastroenterol Hepatol. 2014 Jun;29(6):1308-15.

Grigoriou V, et al. Apoptosis and survival of osteoblast-like cells are regulated by surface attachment. J Biol Chem. 2005 Jan 21;280(3):1733-9.

Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.

Aguzzi MS, et al. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer. 2010 Apr 22;9:84.

  • Select Batch :
    • CS-3266 25741
    • CS-3266 13745
Browsing History
Tags:Arg-Gly-Asp-Ser supplier,Arg-Gly-Asp-Ser purchase,Arg-Gly-Asp-Ser manufacturer,Arg-Gly-Asp-Ser sigma,Arg-Gly-Asp-Ser distributor,cost,Arg-Gly-Asp-Ser buy,Arg-Gly-Asp-Ser for sale
Please enter your email address
Organization name: Email:

Submit success